- £170.78m
- £68.52m
- $38.63m
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Price Monitoring Extension
Brief: Maxcyte And Allogene Therapeutics Sign Clinical And Commercial License Agreement To Enable The Advancement Of Allogeneic Car T (Allocar T™) Therapies
Brief: Maxcyte Signs Agreement With KSQ Therapeutics
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Agreement with KSQ Therapeutics
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Vor Biopharma Clinical and Commercial License
RCS - MaxCyte, Inc. - Presentation at Jefferies Healthcare Conference
RCS - MaxCyte, Inc. - MaxCyte to Present at BIO-Europe 2019
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Result of AGM
Brief: Maxcyte Advances Phase I Clinical Trial Of Lead Carma Mrna-Based Cell Therapy To Third Cohort Of Patients
MaxCyte, Inc. MaxCyte, Inc. - MXCR - MaxCyte Advances Phase I Clinical Trial
RCS - MaxCyte, Inc. - Presentations at Cell & Gene Therapy Congress
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Notification of AGM and Audit Declaration
Brief: Editas Medicine And Maxcyte Announce Clinical And Commercial License Deal For Engineered Cell Medicines
Brief: MaxCyte Inc and Editas Medicine Announce License Agreement For Engineered Cell Medicines
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Editas Clinical and Commercial License Agreement
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Updates on CARMA Platform at Upcoming Meetings
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Results for the Six Months ended 30 June 2019
RCS - MaxCyte, Inc. - Presentation at ICLE 2019
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Notice of Results